Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers

Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers

We previously reported the safety and efficacy of low dose BaP [Bezafibrate (Bez) and Medroxyprogesterone acetate (MPA)] in 20 acute myeloid leukaemia (AML) patients for whom chemotherapy was not an option. This study provided evidence that BaP had anti-AML activity and improved haemopoiesis; absenc...

Full description

Bibliographic Details
Main Authors: Jim Murray, Guy Pratt, Abe Jacob, Fiona Clark, Rachel Blundred, Sonia Fox, Rebecca Bishop, Keith Wheatley, Farhat Khanim, Chris Bunce, Mark Drayson
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Contemporary Clinical Trials Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865418301844

Internet

http://www.sciencedirect.com/science/article/pii/S2451865418301844

Similar Items